文献速递糖尿病肥胖与代谢综合征

将饮酒评估整合进MASLD管理:糖尿病与肥胖照护团队实用指南

Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams.
PubMed 文献 · Diabetes Care · 2026-01-01

本综述指出MASLD在糖尿病和重度肥胖患者中普遍存在,2023年命名修订新增MetALD亚类以承认酒精与代谢因素的协同肝损伤作用。即使轻中度饮酒也可能加速MASLD进展为肝硬化和肝细胞癌,并增加心血管风险;MetALD的全因、癌症相关和肝相关死亡率高于MASLD,因此需用AUDIT问卷和磷脂酰乙醇检测分层评估饮酒。管理以生活方式、减重和GLP-1受体激动剂等药物为主,但MetALD治疗数据有限。

要点

  • MASLD在糖尿病和重度肥胖患者中普遍存在,是美國肝移植常见适应证之一。
  • 2023年命名修订新增MetALD亚类,承认酒精与代谢风险因素协同导致肝损伤。
  • 轻中度饮酒也可能加速MASLD进展为肝硬化、肝癌并增加心血管风险,需用AUDIT和磷脂酰乙醇检测评估。

核心结论

  • 饮酒是MASLD进展的直接肝毒素和间接加重胰岛素抵抗、血脂异常和肥胖的因素。
  • MetALD较MASLD有更高的全因、癌症相关和肝相关死亡率,管理糖尿病和肥胖时需准确评估饮酒。

研究设计与样本

  • 综述,检索范围未在原文中具体报告。

主要发现

  • MASLD影响大多数糖尿病和重度肥胖个体,是美国肝移植最常见适应证之一。
  • 即使轻中度饮酒也可能加速MASLD进展为肝硬化和肝细胞癌,尤其在有代谢疾病者中,并可加重心血管疾病风险。
  • MetALD与MASLD相比,全因、癌症相关和肝相关死亡率增加。
  • 新兴证据提示GLP-1受体激动剂可能减少酒精消费。
  • MetALD的治疗数据有限。

关键数值与推荐

  • 诊断需对饮酒进行分层评估,整合AUDIT问卷和磷脂酰乙醇检测等工具。
  • MASLD管理策略聚焦生活方式改变、减重和GLP-1受体激动剂等药物。

临床怎么用

  • 在糖尿病和肥胖照护路径中整合饮酒评估,使用AUDIT问卷和磷脂酰乙醇检测识别MetALD。
  • 对MASLD患者强调生活方式、减重和GLP-1受体激动剂等药物治疗,同时关注饮酒对肝病和心血管风险的影响。

局限性

  • MetALD的治疗数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects the majority of individuals with diabetes and severe obesity, and is one of the most common indications for liver transplantation in the U.S. Emerging evidence underscores the synergistic and detrimental impact of alcohol and metabolic disease on liver and overall health. In 2023, the nomenclature for steatotic liver disease was revised to include a new subcategory known as MetALD (metabolic dysfunction- and alcohol-associated liver disease), which acknowledges alcohol use as a cofactor in liver injury alongside metabolic risk factors. This review offers key insights into the role of alcohol use as both a direct hepatotoxin and an indirect contributor to insulin resistance, dyslipidemia, and obesity. Notably, even light-to-moderate alcohol intake may hasten MASLD progression to cirrhosis and hepatocellular carcinoma, especially in individuals with existing metabolic disease, and can worsen cardiovascular disease risk. MetALD is associated with increased all-cause, cancer-related, and liver-related mortality in comparison with MASLD, reinforcing the importance of accurate alcohol assessment in managing diabetes and obesity. Diagnosis now requires stratifying alcohol use and integrating tools such as the Alcohol Use Disorders Identification Test (AUDIT) questionnaire and phosphatidylethanol testing. The caveats and use of these tools in clinical practice are discussed. Management strategies for MASLD focus on lifestyle changes, weight loss, and medications such as glucagon-like peptide 1 receptor agonists, with emerging evidence suggesting that these agents may also reduce alcohol consumption. However, treatment data on MetALD are limited. This review offers practical guidance for health care professionals on how to integrate alcohol use into existing, recommended MASLD care pathways.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Alexopoulos AS, Cusi K. Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams. Diabetes Care. 2026. PMID: 42008105. doi:10.2337/dci26-0019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。